sqnm videos

The Bloomberg Insight: Small Caps Dominate the Winner's Circle

Length: 1:37
Rating Average: 4.00 from 1 people
View Count: 44
Author: Bloomberg

Tags: Bio-tech Bloomberg Business Editors Health Hospitality/Food Investing Issues Law Legal NASDAQ:AIPC NASDAQ:AMGN NASDAQ:SQNM NASDAQ:STSI News NYSE:ACV NYSE:ALO NYSE:CRD.B NYSE:EBS NYSE:UST NYSE:VRX Pharma Pick

All Ten Winners of 2008, Mostly Small & Micro Caps: Emergent Biosolutions, Star Scientific, American Italian Pasta, Crawford & Co., Sequenom, Alberto-Culver, Valeant Pharmaceuticals, Alapharma, UST, and Amgen

SQNM - גרף השבוע 25.12.08

Length: 0:28
Rating Average: n/a
View Count: 3
Author: rokerBroker100

Tags: SQNM

גרף השבוע 25.12.08 בהמשך הגרפים יהיו עם ליווי קול כרגע גרף נסיוני.dbursa.co.ilnir.azar@gmail.com

Chart of the Day - SQNM

Length: 2:40
Rating Average: n/a
View Count: 49
Author: thetechtrader

Tags: analysis Boxer Harry picks Sequenom SQNM stock technical

Technical chart analysis by Harry Boxer of TheTechTrader.com on Sequenom Inc (SQNM)

Build your Biotech Basket

Length: 11:6
Rating Average: n/a
View Count: 9
Author: wallstreetmedia

Tags: athx bdx bnf dna dndn gtxi imgn mapp osip sqnm svnt trbn vivo vrus

* Lazard Capital Markets 5th Annual Healthcare Conference* Meridian's Test and Treat program* A non invasive prenatal diagnostic treatment* MAP Pharmaceuticals has new pediatric asthma treatment

Biotechs for the Holidays

Length: 4:49
Rating Average: n/a
View Count: 20
Author: wallstreetmedia

Tags: arql astm bnvi enmd phmd pphm psvd sqnm vicl ziop

* Sequenom works on non-invasive prenatal diagnostic technology* Vical to complete cancer immunotherapy enrollment in mid 2009* Bionovo completed Phase II for menopause and is in Phase III for breast cancer

PREVIEW: Small Cap Focus with Charles Duncan

Length: 1:32
Rating Average: n/a
View Count: 15
Author: BioBusinessTV

Tags: Charles Duncan Genetics Genomic GFDX Health Illumina ILMN Invitrogen IVGN MYGN Myriad Sequanom SQNM

You are Watching:Small Cap Focus, Full Integration, Personalized Medicine, with Charles Duncan.In today's market, where good clinical data and milestones are shadowed by financing prospects, Charles Duncan recommends having at least 2 years cash. Charles also presents a few of the most promising...